CD8A and cancer: In summary, we conclude that POLθ inhibition activates the cGAS/STING pathway in HR-deficient cancers, accounting for the increased production of type I interferons and recruitment of CD8+ T cells and underlying the decreased efficacy of NVB when combined with anti-CD8 treatment.